Table 4.
Prevalence of clinical signs before and after the first treatment with MIL-AL.
| Clinical Signs | Pre-Treatment | First Follow-Up | ||
|---|---|---|---|---|
| N. of Dogs | Prevalence % (95% CI) * | N. of Dogs | Prevalence % (95% CI) * | |
| Loss of weight | 153 | 88.43 (83.67–93.20) |
19 | 10.98 (6.52–15.64) |
| Lymph nodes enlargement | 139 | 80.35 (74.43–86.27) |
104 | 60.12 (52.82–67.41) |
| Skin lesions | 96 | 55.49 (48.09–62.9) |
5 | 2.89 (0.39–5.39) |
| Spleen enlargement | 21 | 12.14 (7.27–17.01) |
23 | 13.29 (8.24–18.35) |
| Polyuria and polydipsia | 44 | 25.43 (18.94–31.92) |
2 | 1.16 (0.00–2.75) |
* The analysis was performed for the first 9 follow-ups.